Scheduled blood removal is well established in people who store too much iron or make too many red cells, preventing organ damage and clotting events. Beyond those groups the long-term gain stays plausible but unproven, while the costs are certain: iron stores fall, oxygen-carrying capacity drops for days, and fainting and bruising are common. (Full Review)

Protocol

Standard voluntary donation

450–500 mL whole blood

Every 8 weeks (United States) or 12 weeks (United Kingdom) for men; every 12 to 16 weeks for women

Ferritin-guided donation

Interval set by ferritin

Ferritin measured at first donation and every fifth; interval extended to 6 months at 15–30 ng/mL and 12 months below 15 ng/mL

Iron-overload induction

450–500 mL weekly or fortnightly

Until ferritin reaches 20–50 ng/mL, then maintenance every 2 to 4 months

Time to effect

Iron-overload induction

Months to years

Time to draw stores down to the ferritin target

Blood pressure

6 weeks

Systolic change seen in metabolic syndrome

Ferritin

1 to 2 sessions

Falls roughly 30 ng/mL per unit removed

Benefits

Medium: Prevention of organ damage in hereditary iron overload; fewer clotting events in polycythemia; lower blood pressure in metabolic syndrome; lower cancer incidence and cancer mortality; remission of porphyria cutanea tarda

Low: Improved insulin sensitivity and liver enzymes in fatty liver disease; lower risk of heart attack; reduced body burden of persistent fluorinated chemicals

Speculative: Slowed skin and connective-tissue aging; improved blood flow through small vessels

Contraindications

Hemoglobin below 13.0 g/dL in men or 12.5 g/dL in women, or ferritin below 30 ng/mL without concurrent iron replacement

Body weight under 50 kg (110 lb)

Pregnancy and the first six months postpartum

Myocardial infarction, unstable angina or stroke within the preceding 6 months, and NYHA Class III–IV heart failure

Severe aortic stenosis, or an uncontrolled arrhythmia

Seizure within the preceding 3 years, or any history of a severe vasovagal reaction with injury

Anemia from any untreated cause, including undiagnosed gastrointestinal blood loss

Key Interactions

Anticoagulants and antiplatelet drugs: Warfarin, apixaban, clopidogrel, aspirin

Antihypertensives and diuretics: Alpha-blockers, thiazides, loop diuretics

Erythropoiesis-stimulating agents and testosterone: Epoetin alfa, darbepoetin, testosterone cypionate

Proton pump inhibitors: Omeprazole, pantoprazole

Over-the-counter analgesics: Aspirin, ibuprofen, naproxen

Iron and vitamin C supplements

Supplements with additive iron-lowering effects: Curcumin, inositol hexaphosphate, green tea catechins, quercetin, calcium

Other interventions: Endurance training, heat and sauna exposure, very-low-carbohydrate or carnivore eating patterns

Risk & Side Effects

High: Iron depletion, falling hemoglobin and donation-related symptoms; vasovagal reactions and fainting; reduced aerobic capacity for days to weeks

Medium: Restless legs syndrome; bruising, arm soreness and nerve irritation

Low: Cardiac events in donors with silent coronary disease; citrate reactions during apheresis

Speculative: Selection of blood stem cell clones; iron deficiency effects on brain function

Monitoring

Marker	Target	Why
Ferritin	50–100 ng/mL maintenance; 20–50 ng/mL induction endpoint	The primary target and the variable the schedule is titrated against
Transferrin saturation	25–35 percent	Distinguishes true iron loading from inflammatory hyperferritinemia
Hemoglobin	13.5–15.5 g/dL in men; 12.5–14.5 g/dL in women	The safety gate before each session and the marker of over-depletion
Hematocrit	40–48 percent in men; 36–44 percent in women	Governs blood viscosity and is the explicit target in red-cell excess
Serum iron and total iron-binding capacity	Serum iron 60–140 µg/dL; total iron-binding capacity 250–400 µg/dL	Completes the panel and allows transferrin saturation to be calculated
High-sensitivity C-reactive protein	Below 1.0 mg/L	Tells whether a raised ferritin reflects iron or inflammation
HFE genotype	No numeric range; whether a loading genotype is present, which sets the ferritin target	Identifies the C282Y and H63D variants that cause hereditary iron loading
Alanine aminotransferase and aspartate aminotransferase	Both below 25 U/L in men and below 20 U/L in women	Detects the liver injury that iron overload causes and that iron reduction may reverse
Fasting insulin and glucose	Fasting insulin below 6 µIU/mL; fasting glucose 75–90 mg/dL	Tracks the insulin-resistance endpoint that iron reduction trials targeted
Seated blood pressure	Below 120/80 mmHg	The one outcome a randomized phlebotomy trial moved substantially

Cadence: Induction — hemoglobin before every session, ferritin every four to six sessions. Maintenance — ferritin, blood count and transferrin saturation every six to twelve months.

Qualitative Assessment

Daytime energy and the presence of unusual breathlessness on stairs or hills
Perceived exertion during habitual training sessions in the two weeks after a removal
Restless, crawling or aching sensations in the legs at night, and how often they disturb sleep
Cognitive clarity and concentration through the afternoon
Recovery time at the collection site and any lightheadedness in the hours afterward
Skin and nail changes, and cold intolerance, which appear when depletion has gone too far

Periodic Phlebotomy for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment